CVRx (NASDAQ:CVRX) Downgraded by Canaccord Genuity Group to Hold

Canaccord Genuity Group lowered shares of CVRx (NASDAQ:CVRX) from a buy rating to a hold rating in a report published on Friday morning, Marketbeat reports. The firm currently has $2.00 target price on the stock, down from their prior target price of $5.00.

A number of other research firms have also weighed in on CVRX. Craig Hallum lowered shares of CVRx from a “buy” rating to a “hold” rating and set a $4.00 target price on the stock. in a research note on Friday, August 7th. Wall Street Zen upgraded shares of CVRx from a “sell” rating to a “hold” rating in a research note on Saturday, October 10th. Lake Street Capital lowered CVRx from a “buy” rating to a “hold” rating and dropped their target price for the company from $14.00 to $3.50 in a report on Friday, August 7th. Piper Sandler lowered CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 target price on the stock. in a report on Friday, August 7th. Finally, William Blair cut CVRx from an “outperform” rating to a “market perform” rating in a research note on Friday. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $3.70.

CVRx Stock Down 40.9%

CVRX stock traded down $0.60 during trading on Friday, reaching $0.87. 5,392,325 shares of the company traded hands, compared to its average volume of 432,611. CVRx has a 12 month low of $0.77 and a 12 month high of $10.28. The company has a market capitalization of $23.14 million, a price-to-earnings ratio of -0.43 and a beta of 0.81. The company has a debt-to-equity ratio of 2.94, a quick ratio of 6.87 and a current ratio of 8.04. The business has a 50 day simple moving average of $2.08 and a 200 day simple moving average of $5.16.

CVRx (NASDAQ:CVRX) last released its earnings results on Thursday, November 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.02). The company had revenue of $13.83 million during the quarter, compared to analyst estimates of $13.93 million. CVRx had a negative return on equity of 152.35% and a negative net margin of 84.93%. On average, equities research analysts anticipate that CVRx will post -2.00 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other CVRx news, COO Brent Binkowski acquired 26,223 shares of the stock in a transaction dated Thursday, August 13th. The stock was acquired at an average price of $2.91 per share, with a total value of $76,308.93. Following the completion of the transaction, the chief operating officer directly owned 56,514 shares in the company, valued at approximately $164,455.74. This trade represents a 86.57% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 16.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CVRx

Several hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. increased its stake in CVRx by 2,137.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 100,937 shares of the company’s stock valued at $177,000 after buying an additional 96,426 shares during the period. State of Alaska Department of Revenue acquired a new stake in CVRx in the third quarter valued at approximately $87,000. Bank of America Corp DE bought a new stake in CVRx in the second quarter worth approximately $102,000. BlackRock Inc. bought a new stake in CVRx in the second quarter worth approximately $6,402,000. Finally, Deutsche Bank AG acquired a new position in shares of CVRx during the 2nd quarter worth $62,000. Institutional investors and hedge funds own 75.27% of the company’s stock.

Key Headlines Impacting CVRx

Here are the key news stories impacting CVRx this week:

• Neutral Sentiment: Trading in CVRx was temporarily paused under a Limit Up-Limit Down (LULD) volatility mechanism. The halt signals unusually volatile trading but does not, by itself, explain the move. Trading halt notice
• Negative Sentiment: CVRx reported Q3 revenue of $13.83 million, below the roughly $13.93 million analyst expectation, and a loss of $0.52 per share versus estimates of about $0.50. Revenue declined year over year, and the company lowered its FY2026 outlook, raising concerns about growth and execution. CVRx reports Q3 revenue decline and lowers outlook
• Negative Sentiment: Canaccord Genuity cut its rating from Buy to Hold and reduced its price target from $5 to $2. William Blair also downgraded the stock, moving from Outperform to Market Perform. The lowered ratings and targets add pressure despite the $2 target remaining above the recent share price. William Blair downgrade

About CVRx

CVRx, Inc (NASDAQ: CVRX) is a medical device company focused on developing and commercializing neuromodulation therapies for patients with cardiovascular diseases. The company’s technology is designed to activate the body’s natural nervous system pathways to help regulate cardiovascular function.

CVRx’s primary product is the Barostim system, an implantable device that delivers electrical stimulation to baroreceptors located near the carotid arteries. By influencing signals between the cardiovascular system and the brain, Barostim is intended to reduce excessive sympathetic nervous system activity and improve symptoms and function in certain patients with heart failure.